【Intro】Single Cell Technology, Inc.

Single Cell Technology, Inc.

Company Introduction

Single Cell Technology (SCT) was established in 2008. We named our antibody discovery technology after the Greek word atheneum, meaning an institute for scientific learning. AbTheneum™ technology was independently developed by merging 8 different fields. SCT has been helping global pharmaceutical companies find sought-after antibodies against unusual or difficult drug targets since 2016.

Brief description of main products or services 

SCT’s AbTheneum™ platform combines micro-fabrication, next generation DNA sequencing (NGS), molecular biology, mechanical engineering, and bioinformatics together with patents and trade secrets. Output from AbTheneum™ is displayed as a compendium of Big Data in what is called the Antibody Atlas™. Each study focused on a different target protein has its own proprietary Antibody Atlas™.  AbTheneum™ has been used to isolate hundreds to thousands of antibodies against various immune-oncology drug targets as well as the spike protein of SARS-CoV-2 virus.  Recent validation experiments showed SCT’s anti-spike antibodies are on par with or better than those developed by Regeneron or Eli Lilly in terms of neutralization potency.